Sorry, your browser doesn't support embedded videos.

Your cells in 3D

Kugelmeiers contributes to and provides accessibility to regenerative medicine, believing it to be a potential for future medical therapies that everyone should have the opportunity to commit towards. We developed as a result of 18 years of research and dedication in the field of transplant surgery,  cell therapy and developmental biology a technology allowing us to make an impact on islet, liver and many other cell therapies that rely on 3D spheroids that need a medical quality platform.

Our first product, the Sphericalplate 5D, is a platform enabling advanced 3D culturing, as well as safe clinical use of stem cells. Cell culture geometry and surface are decisive for communication in between stem cells and their early differentiation. This is a prerequisite for safe regenerative medicine applications. During their development stem cells need physiological enviroment in order to reduce the risk of uncontrolled differentiation. 

We are embarking on an exciting growth phase in the field of advanced cell therapies. The global cell culture research market is changing form 2D to 3D. The Sphericalplate 5D is the solution covering the entire application range with unrivaled user advantages.

OUR TECHNOLOGY

Spheroid size controlled by initial seeding density

Sharp borders prevent settlement of cells on an area other than microcavities

Uniform spheroid formation

Micro structured well bottom: 750 micro cavities per well

Plate made from COC for optimal imaging properties

Technology

  • Designed for the clinical cell therapy in regenerative medicine
  • Patented 3D design for correct cell programming and the highest cell safety 
  • Patented SuSoS medical grade nanocoating surface
  • Translation (from bench to bedside): the entire way from lab to clinics is covered
  • Clinical certification starting 2020 with a human trial for diabetes

USP’s

  • Hundreds to thousands of clinical grade cell spheroids with one pipette move
  • Medical device class 2a in development
  • Freely scalable
  • Space and time effective
  • Easy and precise control of spheroid formation
  • Developed for automation (screening and handling)

Products

  • Sphericalplate 5D on market (research and industry product)
  • Sphericalplate 5D Medical for human therapeutic use (2020)
  • Further products and technologies in development

This plate will be our future standard for cell cluster production. You can do things with it which you just cannot do with other platforms. 

Prof. Dr. Michael Raghunath – Life Sciences. ZHAW Wädenswil

This plate is a game changer. Everyone who needs a lot of clusters needs this plate!

Prof. Dr. Dr. Maximilian Y. Emmert – Institute for Regenerative Medicine, IREM, University of Zurich

Cells Successfully Cultivated in the Sphericalplate 5D

human embryonic stem cells

mouse embryonic stem cell line (HM-1)

human bone marrow-derived mesenchymal stromal cells

human adipose-derived mesenchymal stromal cells

human islet cells

rat islet cells

mouse islet cells

human glioblastoma cell line 

human prostate cancer cell line

human adrenal gland cancer cell line

human breast cancer cell line (MCF-7)

human A549 cell line from lung carcinoma

mouse 3T3 fibroblast cell line

human umbilical vein endothelial cell line (huVEC)

human liver carcinoma cell line (HepG2)

human pluripotent stem cell line (Hs181)

human osteosarcoma cell line (Saos-2)

human caucasian fetal lung cell line (WI 38)

human amniotic epithelial cells (hAEC)

For introductory offer please contact: info@kugelmeiers.com

Our company was founded in 2015 as a spin-off from the University of Zurich in Switzerland. We are a team of 22 specialists who develop and market cutting-edge 3D cell culture technologies. In 2020, we plan to begin the first human trial, together with four leading European transplant centres.

Contact

Kugelmeiers Ltd.

Bahnhofstrasse 40
8703 Erlenbach
Switzerland

www.kugelmeiers.com
info@kugelmeiers.com

Contact

Contact

Kugelmeiers Ltd.

Bahnhofstrasse 40
8703 Erlenbach
Switzerland

www.kugelmeiers.com
info@kugelmeiers.com

02/24/2024 05:40:59
  • Home | The Route to Recovery
  • In this issue
  • Mimotopes
  • Contents
  • News
  • VEGA Company Insight
  • VEGA Australia
  • Covid-19 executive briefing by GlobalData
  • Identifying a viable Covid-19 vaccine candidate and steps needed for its successful implementation
  • Impact of Covid-19 on patients with hepatocellular carcinoma
  • NSF
  • Novavax to receive $1.6B from Operation Warp Speed for the development of Covid-
  • FDA winners and losers in Covid-19 therapies
  • Pfeiffer Vacuum
  • Trials delayed due to Covid-19 begin to resume
  • ILC Dover
  • The pharma industry briefing
  • From rare diseases to Covid-19: charting the history of Genomics England
  • Covid-19: how will pharma cope with a looming recession?
  • Pandemic logistics: guaranteeing equitable access
  • Pandemic logistics: Resolving manufacturing and distribution challenges
  • Kugelmeiers
  • Q&A: how to find the right clinical trial participants with Innovative Trials
  • Recce Pharma: a new frontier in the fight against AMR
  • Autism pipeline: are better therapies in sight?
  • How a new crystallography technique may speed up drug development
  • Psychedelics: a game-changer in mental health?
  • Graph technology: the remedy for broken supply chains is connected data
  • Deals in brief powered by GlobalData
  • The key list powered by GlobalData
  • Global markets and indices powered by GlobalData
  • Macro-economic indicators (1 of 2) powered by GlobalData
  • Macro-economic indicators (2 of 2) powered by GlobalData
  • Events
  • Next issue
07/22/2020 00:00:00